-- 米国住宅ローン銀行協会(MBA)は水曜日、金利低下に伴い先週の住宅ローン申請件数が増加したと発表した。マクロ経済の不確実性にもかかわらず、堅調な労働市場が住宅需要を支えているという。 ローン申請件数を測定する市場総合指数は、季節調整済みで金曜日までの1週間で7.9%上昇した。季節調整なしの場合は9%上昇。 MBAのチーフエコノミスト、マイク・フラタントン氏は、「先週の住宅ローン金利は、中東の停戦と原油価格の下落傾向に金融市場が好反応を示したことで低下した」と述べた。「地政学的な不確実性にもかかわらず、住宅需要は依然として堅調な雇用市場に支えられており、昨年に比べて在庫水準が高いことから、国内のほとんどの地域で住宅購入者は買い手市場を経験している」。 融資残高が83万2750ドル以下の30年固定金利住宅ローンの平均金利は、前週の6.42%から6.35%に低下した。当該金額を超えるローン残高の場合、金利は6.48%から6.43%に低下した。15年ローンの金利は、前週比で5.85%から5.75%に低下した、と報告書は述べている。 火曜日遅く、ドナルド・トランプ米大統領はイランとの2週間の停戦合意を延長したが、イランの港湾に対する海上封鎖は継続すると述べた。 連邦住宅局(FHA)が保証する30年固定金利住宅ローンの金利は、前週の6.14%から6.10%に低下した、とMBA(全米抵当銀行協会)は水曜日に発表した。初めて住宅を購入する人がよく利用し、頭金が少なくて済むFHAローンの割合は、申請総数の18.2%で横ばいだった。 借り換え指数は前週比で6%上昇し、季節調整済みの住宅購入指数は10%急上昇した、と報告書は述べている。 今週初め、Redfinが行った調査によると、3月の米国の住宅売却者数は購入者数をほぼ過去最高水準の割合で上回ったことが明らかになった。
Related Articles
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%